HER-2 targeted drugs, including trastuzumab and lapatinib (LPTN), are able to suppress the dimerization and kinase activity of HER2-positive cancers, resulting in significantly improved clinical outcomes in HER-2-positive breast cancer patients. This evidence concerns the gene ERBB2 and cancer.